Ray Dalio's UTHR Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 64,595 shares of United Therapeutics Corporation (UTHR) worth $31.47 M, representing 0.11% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in UTHR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 86,054 shares. Largest reduction occurred in Q3 2025, reducing 179,053 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +48,530 | Add 302.09% | 64,595 | $487.25 |
| Q3 2025 | -179,053 | Reduce 91.77% | 16,065 | $419.21 |
| Q2 2025 | +1,334 | Add 0.69% | 195,118 | $287.35 |
| Q1 2025 | +86,054 | Add 79.88% | 193,784 | $308.27 |
| Q4 2024 | +45,975 | Add 74.45% | 107,730 | $352.84 |
| Q3 2024 | +49,003 | Add 384.28% | 61,755 | $358.35 |
| Q2 2024 | +4,802 | Add 60.40% | 12,752 | $318.55 |
| Q1 2024 | -1,069 | Reduce 11.85% | 7,950 | $229.72 |
| Q4 2023 | -9,128 | Reduce 50.30% | 9,019 | $219.89 |
| Q3 2023 | -22,658 | Reduce 55.53% | 18,147 | $225.87 |
| Q2 2023 | -460 | Reduce 1.11% | 40,805 | $220.75 |
| Q1 2023 | +16,161 | Add 64.38% | 41,265 | $223.96 |
| Q4 2022 | -19,113 | Reduce 43.23% | 25,104 | $278.09 |
| Q3 2022 | -10,209 | Reduce 18.76% | 44,217 | $209.38 |
| Q2 2022 | +54,426 | New Buy | 54,426 | $235.64 |
| Q2 2019 | -9,124 | Sold Out | 0 | $0.00 |
| Q1 2019 | +9,124 | New Buy | 9,124 | $117.38 |
| Q4 2018 | -53,726 | Sold Out | 0 | $0.00 |
| Q3 2018 | +8,401 | Add 18.54% | 53,726 | $127.87 |
| Q2 2018 | -116,024 | Reduce 71.91% | 45,325 | $113.16 |
| Q1 2018 | +67,626 | Add 72.16% | 161,349 | $112.36 |
| Q4 2017 | +953 | Add 1.03% | 93,723 | $147.95 |
| Q3 2017 | +18,802 | Add 25.42% | 92,770 | $117.19 |
| Q2 2017 | +15,876 | Add 27.33% | 73,968 | $129.73 |
| Q1 2017 | +14,187 | Add 32.31% | 58,092 | $135.37 |
| Q4 2016 | -69,900 | Reduce 61.42% | 43,905 | $143.42 |
| Q3 2016 | +49,705 | Add 77.54% | 113,805 | $118.08 |
| Q2 2016 | -21,733 | Reduce 25.32% | 64,100 | $105.91 |
| Q1 2016 | +57,672 | Add 204.79% | 85,833 | $111.43 |
| Q4 2015 | +28,161 | New Buy | 28,161 | $156.60 |
Ray Dalio's United Therapeutics Corporation Investment FAQs
Ray Dalio first purchased United Therapeutics Corporation (UTHR) in Q4 2015, acquiring 28,161 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held United Therapeutics Corporation (UTHR) for 30 quarters since Q4 2015.
Ray Dalio's largest addition to United Therapeutics Corporation (UTHR) was in Q1 2025, adding 193,784 shares worth $59.74 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 64,595 shares of United Therapeutics Corporation (UTHR), valued at approximately $31.47 M.
As of the Q4 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.11% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in United Therapeutics Corporation (UTHR) was 195,118 shares, as reported at the end of Q2 2025.